January Effect 2005 Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : January Effect 2005

IWM 251.39

+0.2%

Dec 9 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Q. who wrote (46)	1/11/2005 10:29:20 PM
From: Q.	Read Replies (1) of 76

Update on my results: As compared to Dec. 31: original portfolio: down 8.5% actual portfolio: down 7.3% Russell 2000: down 6.2% actual portfolio: PARS sold @ 1.25 Jan 4. Today was another down day in the ongoing correction, which is hitting small caps harder than blue chips. My best performer is at breakeve. That's LIPD. It put out an 8k today disclosing a letter to shareholders that touts the company's prospects. Here's an excerpt: Dear Stockholder: We expect that 2005 will be the year Lipid Sciences springboards from a pre-clinical stage company to being poised to launch a human clinical trial for our proprietary selective HDL delipidation technology. Why am I so bullish as we enter this new phase of your Company’s development? Today we have submitted a pre-Investigational Device Exemption packet to the Food and Drug Administration. That action positions us one step closer to our goal of the initiation of a human clinical trial for our HDL Therapy platform. The information submitted to the FDA is based on solid scientific data, which has been reviewed by our Scientific Advisory Board, that demonstrates that researchers have successfully used Lipid Sciences’ proprietary delipidation process to turn good cholesterol into great cholesterol and thus remove arterial plaque at a greater rate. Dr. Frank M. Sacks, Professor of Cardiovascular Disease Prevention, Harvard School of Public Health, and a member of Lipid Sciences’ Scientific Advisory Board, was invited to present the Company’s breakthrough selective delipidation data at the American Heart Association’s Scientific Session 2004, a major annual health conference that was held in November.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next